Members of the All.Can Polska Steering Group met on January 9th 2025 to summarize the
activities of the Initiative in 2024 and set goals and areas that All.Can Polska plans to support
in 2025.
The meeting brought together numerous medical experts, representatives of patient
organizations, healthcare system specialists, and pharmaceutical industry who discussed
improving the efficiency of oncology care in Poland.
The meeting was chaired by Elżbieta Łapot representing Bristol Myers Squibb and the
Chairman of the Presidium Szymon Chrostowski.
Szymon Chrostowski summarized the activities of All.Can Poland in 2024, highlighting the
main activities, including the preparation of another report “Diagnosis of changes in oncology
and hematooncology care in 2023” – for the first time addressing not only oncology but also
the dynamically developing field of hematooncology. He also mentioned the publication of
the report “Barriers to accessing innovative treatment in selected cancers” and collaboration
with EFPIA on a project promoting oncology screening, in accordance with European Union
guidelines. He also provided information about All.Can’s activity on social media platforms –
Facebook, X, and LinkedIn. —————————————————————————————————————————
Eduardo Pisani, CEO All.Can International, summarized the activities on the international
stage in 2024 and outline plans for 2025, among them Cancer Care Efficiency Action Guide
implementation, person-centred cancer care pathways and collaboration with National
Initiatives on EFPIA EU Screening Recommendation.
Eduardo Pisani said that both in the international and national level we can be proud of the
work that All.Can is undertaking. We have built over the past few years numerous
collaborations, we have developed several policy research which are being appreciated by
national international organizations from the OECD and the EU institutions.
Eduardo Pisani thanked All.Can Polska for the good work on the screening project – I want to
thank you for being part of this project and Poland has an opportunity to deliver valuable input
in this area at European level as well – he said. He also expressed hope that there will be
possibilities to continue collaborating effectively on further projects within the framework of
the global All.Can strategy, such as initiatives promoting the Cancer Care Efficiency Action
Guide
(https://www.all-can.org/what-we-do/policy-research/action-guide-for-efficient-cancer
care/). —————————————————————————————————————————
The All.Can Poland operates with the financial support of the companies
Bristol Myers Squibb (lead sponsor) as well as Amgen, Eli Lilly, Gilead and Takeda.
The next item on the agenda was a debate on the conclusions and recommendations of the
report “Barriers to accessing innovative treatment in selected cancers” featuring PhD
Małgorzata Gałązka-Sobotka, Professor Maciej Krzakowski and Professor Andrzej
Tysarowski, moderated by Szymon Chrostowski the Chairman of the Presidium All.Can
Polska. Professor Maciej Krzakowski emphasized the significant progress made in accessing
lung cancer treatment and discussed the unmet needs in both lung and kidney cancer areas,
highlighting the importance of prevention and appropriate diagnostics. He expressed hope
that the report would be recognized and read by decision-makers, as it contains many
conclusions that should be acknowledged and implemented.
Professor Andrzej Tysarowski addressed the need to improve access to genetic and molecular
diagnostics, which is crucial for selecting optimal therapy, and consequently, for the chances
of effective treatment. The expert also pointed out the necessity of shortening diagnosis times
and simplifying logistics, for example, by issuing referrals for genetic testing simultaneously
with referrals for histopathological examinations.
PhD Małgorzata Gałązka-Sobotka discussed the issue of adequate funding and the need to
prioritize access to innovations. According to the expert, an essential area of focus for all
stakeholders interested in further improving the efficiency of oncology care should be
prevention, which, despite many years of discussion and actions taken, still yields insufficient
results. The need to intensify efforts to improve access to modern diagnostics was also
supported by Professor Anna Latos-Bieleńska, National Consultant in the field of clinical
genetics. —————————————————————————————————————————
The next debate focused on the issue of access to cancer screening. The moderator,
Aleksandra Rudnicka – representative of patients’ organization, invited Professor Joanna
Didkowska and Professor Joanna Chorostowska-Wynimko to this important discussion. The
topic of prevention, particularly access to screenings is very significant – as the earlier a cancer
is detected, the greater and better the chances for effective treatment. The experts
acknowledged that there is still much to be done in this area. As emphasized by Professor
Joanna Didkowska, the participation rate in cervical cancer screening is only 15%, which is why
vaccination against HPV should be prioritized. In the case of colorectal cancer, it is important
to introduce FIT tests, and for breast cancer, tomography is crucial.
Professor Joanna Chorostowska-Wynimko presented the results of the project “SOLACE – The
strengthening the screening of lung cancer in Europe”. She presented important conclusions
on the actions that should be taken to ensure satisfactory screening rates. Education for
medical staff and strong engagement from primary care physicians, as well as reaching the
appropriate target groups with information about testing opportunities using the most
suitable communication methods, including involving local communities, are necessary.
Professor Chorostowska-Wynimko acknowledged that there are many challenges associated
with the lung cancer screening program due to technological, organizational, quality, and
The All.Can Poland operates with the financial support of the companies
Bristol Myers Squibb (lead sponsor) as well as Amgen, Eli Lilly, Gilead and Takeda.
target group (high-risk) criteria. However, using appropriate tools and putting in the right
effort can yield satisfactory results, as demonstrated by the pilot program conducted in the
Lublin Voivodeship. —————————————————————————————————————————
The final presentation by Professor Piotr Rutkowski concerned the National Oncology
Strategy. Professor Rutkowski discussed the process of implementing the NOS and key actions
taken in 2024, such as the establishment of a working group that, in collaboration with the e
Health Center, developed a final, clinically acceptable version of the e-DILO, as well as
conducting a pilot program for the e-DILO card in selected oncology centers. —————————————————————————————————————————
In conclusion, Szymon Chrostowski presented plans for 2025, including the release of another
edition of the report “Diagnosis of changes in oncology and hematooncology care in 2024”
which is to be published in March, as well as further work on the publication and medialization
of the report concerning “Oncological screening programs”. He urged participants and all
members of All.Can Polska to send comments and proposals for actions in 2025.”